{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T14:04:13Z","timestamp":1793023453514,"version":"4.5.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T00:00:00Z","timestamp":1739836800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100030732","name":"MSD","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100030732","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013955","name":"Astellas Pharma BV","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013955","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009109","name":"Bayer Pharma AG","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009109","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.clgc.2025.102317","type":"journal-article","created":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T13:10:06Z","timestamp":1739884206000},"page":"102317","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Learning From Evidence: Changes in Real-World Use of Second Androgen Receptor Targeted Treatments in Metastatic Castration-Resistant Prostate Cancer (mCRPC)"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-5354-8279","authenticated-orcid":false,"given":"Dianne","family":"Bosch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-9986-2416","authenticated-orcid":false,"given":"Kim J.M.","family":"van der Velden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9086-6558","authenticated-orcid":false,"given":"Tom","family":"Belleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Welmoed K.","family":"van Deen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5223-2549","authenticated-orcid":false,"given":"Andr\u00e9 M.","family":"Bergman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8754-1210","authenticated-orcid":false,"given":"Maarten J.","family":"van der Doelen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfons J.M.","family":"van den Eertwegh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winald R.","family":"Gerritsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2559-9254","authenticated-orcid":false,"given":"Reindert J.A.","family":"van Moorselaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5277-6586","authenticated-orcid":false,"given":"Diederik M.","family":"Somford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Metin","family":"Tascilar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans M.","family":"Westgeest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carin A.","family":"Uyl-de Groot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter F.A.","family":"Mulders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malou C.P.","family":"Kuppen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8002-1869","authenticated-orcid":false,"given":"Inge M.","family":"van Oort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"16","key":"10.1016\/j.clgc.2025.102317_bib0001","doi-asserted-by":"crossref","first-page":"4610","DOI":"10.1158\/1078-0432.CCR-21-1625","article-title":"Evolution of castration-resistant prostate cancer in ctDNA during sequential androgen receptor pathway inhibition","volume":"27","author":"Annala","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clgc.2025.102317_bib0002","unstructured":"N. Mottet, R.C.N. van den Bergh, E. Briers, et al. Expert Patient Advocate (European Prostate Cancer Coalition\/Europa UOMO), EAU - EANM - ESTRO - ESUR - ISUP - SIOG guidelines on prostate cancer. 2024, https:\/\/uroweb.org\/guidelines\/prostate-cancer\/chapter\/treatment. Accessed Feb 23 2024."},{"issue":"3","key":"10.1016\/j.clgc.2025.102317_bib0003","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1038\/s41391-021-00344-1","article-title":"The effects of new life-prolonging drugs for metastatic castration-resistant prostate cancer (mCRPC) patients in a real-world population","volume":"24","author":"Westgeest","year":"2021","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"10","key":"10.1016\/j.clgc.2025.102317_bib0004","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/j.ctrv.2015.08.002","article-title":"Understanding and overcoming the mechanisms of primary and acquired resistance to abiraterone and enzalutamide in castration resistant prostate cancer","volume":"41","author":"Buttigliero","year":"2015","journal-title":"Cancer Treat Rev"},{"issue":"26","key":"10.1016\/j.clgc.2025.102317_bib0005","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1056\/NEJMoa1911206","article-title":"Cabazitaxel versus Abiraterone or enzalutamide in metastatic prostate cancer","volume":"381","author":"de Wit","year":"2019","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.clgc.2025.102317_bib0006","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1016\/S1470-2045(19)30688-6","article-title":"Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial","volume":"20","author":"Khalaf","year":"2019","journal-title":"Lancet Oncol"},{"issue":"15","key":"10.1016\/j.clgc.2025.102317_bib0007","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1002\/pros.24069","article-title":"The clinical benefit of sequential therapy with androgen receptor axis-targeted agents alone in patients with castration-resistant prostate cancer: a propensity score-matched comparison study","volume":"80","author":"Naito","year":"2020","journal-title":"Prostate"},{"issue":"3","key":"10.1016\/j.clgc.2025.102317_bib0008","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.clgc.2017.11.007","article-title":"Comparison of alternative androgen receptor-axis-targeted agent (ARATA) and Docetaxel as second-line therapy for patients with metastatic castration-resistant prostate cancer with progression after initial ARATA in real-world clinical practice in Japan","volume":"16","author":"Miyake","year":"2018","journal-title":"Clin Genitourin Cancer"},{"issue":"11","key":"10.1016\/j.clgc.2025.102317_bib0009","doi-asserted-by":"crossref","first-page":"500.e1","DOI":"10.1016\/j.urolonc.2018.08.002","volume":"36","author":"Oh","year":"2018","journal-title":"Urol Oncol"},{"issue":"8","key":"10.1016\/j.clgc.2025.102317_bib0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/jcm8081251","article-title":"Comparison of radiographic progression-free survival and PSA response on sequential treatment using Abiraterone and Enzalutamide for newly diagnosed castration-resistant prostate cancer: a propensity score matched analysis from multicenter cohort","volume":"8","author":"Komura","year":"2019","journal-title":"J Clin Med"},{"issue":"1","key":"10.1016\/j.clgc.2025.102317_bib0011","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1002\/pros.23246","article-title":"Comparing sequencing of abiraterone and Enzalutamide in men with metastatic castration-resistant prostate cancer: a retrospective study","volume":"77","author":"Maughan","year":"2017","journal-title":"Prostate"},{"issue":"1","key":"10.1016\/j.clgc.2025.102317_bib0012","doi-asserted-by":"crossref","first-page":"e46","DOI":"10.1016\/j.clgc.2019.09.011","article-title":"Sequential use of androgen receptor axis-targeted agents in chemotherapy-naive castration-resistant prostate cancer: a multicenter retrospective analysis with 3-year follow-up","volume":"18","author":"Kobayashi","year":"2020","journal-title":"Clin Genitourin Cancer"},{"issue":"6","key":"10.1016\/j.clgc.2025.102317_bib0013","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/iju.13346","article-title":"Exploring the optimal sequence of abiraterone and enzalutamide in patients with chemotherapy-naive castration-resistant prostate cancer: the Kyoto-Baltimore collaboration","volume":"24","author":"Terada","year":"2017","journal-title":"Int J Urol"},{"issue":"5","key":"10.1016\/j.clgc.2025.102317_bib0014","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1002\/pros.23141","article-title":"Prognostic factors for clinical outcomes in patients with metastatic castration resistant prostate cancer treated with sequential novel androgen receptor-directed therapies","volume":"76","author":"Nadal","year":"2016","journal-title":"Prostate"},{"issue":"2","key":"10.1016\/j.clgc.2025.102317_bib0015","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.clgc.2017.09.008","article-title":"Abiraterone followed by Enzalutamide versus Enzalutamide followed by Abiraterone in chemotherapy-naive patients with metastatic castration-resistant prostate cancer","volume":"16","author":"Matsubara","year":"2018","journal-title":"Clin Genitourin Cancer"},{"issue":"4","key":"10.1016\/j.clgc.2025.102317_bib0016","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.euo.2019.09.005","article-title":"Real-world outcomes of sequential androgen-receptor targeting therapies with or without interposed life-prolonging drugs in metastatic castration-resistant prostate cancer: results from the Dutch castration-resistant prostate Cancer registry","volume":"4","author":"Kuppen","year":"2021","journal-title":"Eur Urol Oncol"},{"issue":"4","key":"10.1016\/j.clgc.2025.102317_bib0017","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/s41391-020-0222-6","article-title":"Sequential therapy of abiraterone and enzalutamide in castration-resistant prostate cancer: a systematic review and meta-analysis","volume":"23","author":"Mori","year":"2020","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.clgc.2025.102317_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2020.102152","article-title":"Optimal treatment sequencing of abiraterone acetate plus prednisone and enzalutamide in patients with castration-resistant metastatic prostate cancer: a systematic review and meta-analysis","volume":"93","author":"Cassinello","year":"2021","journal-title":"Cancer Treat Rev"},{"issue":"19","key":"10.1016\/j.clgc.2025.102317_bib0019","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/cancers13194951","article-title":"Treatment pattern and outcomes with systemic therapy in men with metastatic prostate cancer in the real-world patients in the United States","volume":"13","author":"Swami","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"9","key":"10.1016\/j.clgc.2025.102317_bib0020","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.annonc.2020.06.011","article-title":"Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Parker","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2025.102317_bib0021","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2024.104286","article-title":"Second-line treatment options in metastatic castration-resistant prostate cancer after progression on first-line androgen-receptor targeting therapies: a systematic review and Bayesian network analysis","volume":"196","author":"Xiong","year":"2024","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.clgc.2025.102317_bib0022","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.thromres.2021.10.025","article-title":"Reasons for non-adherence to thromboprophylaxis prescribing guidelines in atrial fibrillation in Western Australia: a qualitative descriptive study of general practitioners' views","volume":"208","author":"Gebreyohannes","year":"2021","journal-title":"Thromb Res"},{"issue":"12","key":"10.1016\/j.clgc.2025.102317_bib0023","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1258\/jrsm.2011.110180","article-title":"The answer is 17 years, what is the question: understanding time lags in translational research","volume":"104","author":"Morris","year":"2011","journal-title":"J R Soc Med"},{"issue":"4","key":"10.1016\/j.clgc.2025.102317_bib0024","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1108\/09696471111132504","article-title":"The learning conference knowledge creation through participation and publication","volume":"18","author":"Louw","year":"2011","journal-title":"Learn Organ"},{"issue":"3","key":"10.1016\/j.clgc.2025.102317_bib0025","first-page":"482","article-title":"Valuing technology-enhanced academic conferences for continuing professional development. A systematic literature review","volume":"46","author":"Spilker","year":"2020","journal-title":"Prof Dev Educ"},{"issue":"15","key":"10.1016\/j.clgc.2025.102317_bib0026","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/cancers15153808","article-title":"Reliability and efficiency of the CAPRI-3 metastatic prostate cancer registry driven by artificial intelligence","volume":"15","author":"Bosch","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"12","key":"10.1016\/j.clgc.2025.102317_bib0027","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1200\/JCO.2015.64.2702","article-title":"Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the prostate cancer clinical trials Working Group 3","volume":"34","author":"Scher","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2025.102317_bib0028","unstructured":"EAU Guidelines - prostate cancer - summary of changes. 2024, https:\/\/uroweb.org\/guidelines\/prostate-cancer\/summary-of-changes\/2021. Accessed Feb 23 2024."},{"key":"10.1016\/j.clgc.2025.102317_bib0029","article-title":"Moving from a registry to a learning health system: a case study of a Dutch prostate cancer registry","volume":"2024","author":"Belleman","year":"2025","journal-title":"Learn Health Syst"},{"issue":"4","key":"10.1016\/j.clgc.2025.102317_bib0030","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1056\/NEJMoa1704174","article-title":"Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer","volume":"377","author":"Fizazi","year":"2017","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.clgc.2025.102317_bib0031","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1056\/NEJMoa1903835","article-title":"Enzalutamide with standard first-line therapy in metastatic prostate cancer","volume":"381","author":"Davis","year":"2019","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.clgc.2025.102317_bib0032","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1702900","article-title":"Abiraterone for prostate cancer not previously treated with hormone therapy","volume":"377","author":"James","year":"2017","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.clgc.2025.102317_bib0033","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.annonc.2023.02.015","article-title":"Updated treatment recommendations for prostate cancer from the ESMO Clinical Practice Guideline considering treatment intensification and use of novel systemic agents","volume":"34","author":"Fizazi","year":"2023","journal-title":"Ann Oncol"},{"issue":"14","key":"10.1016\/j.clgc.2025.102317_bib0034","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1016\/j.ejca.2015.06.128","article-title":"Prior long response to androgen deprivation predicts response to next-generation androgen receptor axis targeted drugs in castration resistant prostate cancer","volume":"51","author":"Loriot","year":"2015","journal-title":"Eur J Cancer"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767325000187?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767325000187?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T07:25:44Z","timestamp":1754551544000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767325000187"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S1558767325000187"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2025.102317","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Learning From Evidence: Changes in Real-World Use of Second Androgen Receptor Targeted Treatments in Metastatic Castration-Resistant Prostate Cancer (mCRPC)","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2025.102317","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102317"}}